Odin’s location in Somerset, New Jersey includes over 75,000 square feet of warehousing, office, and laboratory space originally built by Merck Pharmaceuticals. This facility is currently being upgraded to an ultra-modern sterile liquid and lyophilization processing plant that will fill injectable and ophthalmic dosage forms utilizing the most innovative high velocity and high-pressure equipment. Plans are also being executed to expand the facility with an additional 40,000 square feet of shell coverage to be used for distribution and laboratories.
As a Research and Development organization, Odin is compliant and/or registered with all regulatory organizations, including but not limited to:
As the company develops manufacturing capabilities, it anticipates timely auditing and issuance of cGMP compliance by the FDA. Executive leadership has remained compliant with the agency through many past audits with previous companies, including several audits of aseptic processing operations.
Odin Pharmaceuticals is actively developing several difficult-to-develop and difficult-to-manufacture products. The company’s product focus spans multiple dosage forms utilizing aseptic processing and terminal sterilization:
The firm’s products incorporate advanced pharmaceutical technologies, including:
The formulation team focuses heavily on preformulation, analysis, and scale-up.
Odin plans to market its products to retail pharmacies, ophthalmologists, optometrists, physicians, veterinarians, hospitals, clinics, wholesalers, distributors, group purchasing organizations, and government agencies. The firm has relationships with all major customers. Below is a selected list of accounts: